Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI7219 in healthy subjects
NCT03362593Phase 1Terminated
- Sponsor
- MedImmune
- Start
- Dec 2017
- Primary completion
- May 2020
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing MEDI7219 with Placebo (2 arms). Primary endpoint: Number of subjects with Adverse Events at Day 63. Started Dec 2017; status: terminated.
02
Drugs
MEDI7219
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03362593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03362593.